HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (28) Citing Articles via Google Scholar Google Scholar Articles by Dowell, J. A. Articles by Weston, I. E. Search for Related Content PubMed PubMed Citation Articles by Dowell, J. A. Articles by Weston, I. E. Social Bookmarking                   What's this?

Assessment of the Safety and Pharmacokinetics of Anidulafungin When Administered With Cyclosporine

From Vicuron Pharmaceuticals, Inc, King of Prussia, Pennsylvania (Dr Dowell, Dr Stogniew, Dr Krause, Dr Henkel) and MDS Pharma Services, Phoenix, Arizona (Dr Weston).

Anidulafungin is a novel antifungal agent of the echinocandin class that is intended for the treatment of invasive fungal disease. It is likely that anidulafungin will be coadministered with cyclosporine. In vitro studies and clinical studies were performed to evaluate the effect of anidulafungin on cyclosporine metabolism and to investigate the safety and pharmacokinetics of anidulafungin when concomitantly administered with cyclosporine. The potential for anidulafungin to inhibit the metabolism of cyclosporine was evaluated by pooled human hepatic microsomal protein fractions in vitro, incubating ³H-cyclosporine with different concentrations of anidulafungin. The safety of coadministration and the effects of cyclosporine on the pharmacokinetics of anidulafungin were assessed in a multiple-dose, open-label clinical study of 12 healthy volunteers. Subjects received a 200-mg intravenous loading dose of anidulafungin, followed by a daily 100-mg intravenous maintenance dose on days 2 through 8. An oral solution of cyclosporine (Neoral oral solution; 100 mg/mL) 1.25 mg/kg was also administered to subjects twice daily on days 5 through 8. In the in vitro study, the addition of anidulafungin had no effect on cyclosporine metabolism by human hepatic microsomal protein fractions. In the clinical study, no dose-limiting toxicities or serious adverse events occurred. A small increase in anidulafungin concentrations and drug exposure (22%) was observed after 4 days of dosing with cyclosporine and was not considered to be clinically relevant. The results support the concomitant use of anidulafungin and cyclosporine without the need for dosage adjustments of either drug.

Key Words: Cyclosporine • anidulafungin • drug interactions • drug safety • pharmacokinetics

Address for reprints: James A. Dowell, PhD, Director Pharmacokinetics and Pharmacology, Vicuron Pharmaceuticals, 455 South Gulph Road Suite 310, King of Prussia, PA 19406.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L. Wang, M. Tao, E. Wendt-Pienkoski, U. Galm, J. M. Coughlin, and B. Shen Functional Characterization of tlmK Unveiling Unstable Carbinolamide Intermediates in the Tallysomycin Biosynthetic Pathway J. Biol. Chem., March 27, 2009; 284(13): 8256 - 8264. [Abstract] [Full Text] [PDF]

				B. D. Damle, J. A. Dowell, R. L. Walsky, G. L. Weber, M. Stogniew, and P. B. Inskeep In Vitro and In Vivo Studies To Characterize the Clearance Mechanism and Potential Cytochrome P450 Interactions of Anidulafungin Antimicrob. Agents Chemother., March 1, 2009; 53(3): 1149 - 1156. [Abstract] [Full Text] [PDF]

				J. A. Dowell, M. Stogniew, D. Krause, and B. Damle Anidulafungin Does Not Require Dosage Adjustment in Subjects With Varying Degrees of Hepatic or Renal Impairment J. Clin. Pharmacol., April 1, 2007; 47(4): 461 - 470. [Abstract] [Full Text] [PDF]

				J. A. Dowell, M. Stogniew, D. Krause, T. Henkel, and B. Damle Lack of Pharmacokinetic Interaction Between Anidulafungin and Tacrolimus J. Clin. Pharmacol., March 1, 2007; 47(3): 305 - 314. [Abstract] [Full Text] [PDF]

				J. Cota, M. Carden, J. R. Graybill, L. K. Najvar, D. S. Burgess, and N. P. Wiederhold In Vitro Pharmacodynamics of Anidulafungin and Caspofungin against Candida glabrata Isolates, Including Strains with Decreased Caspofungin Susceptibility Antimicrob. Agents Chemother., November 1, 2006; 50(11): 3926 - 3928. [Abstract] [Full Text] [PDF]

				M. I. Morris and M. Villmann Echinocandins in the management of invasive fungal infections, part 1. Am. J. Health Syst. Pharm., September 15, 2006; 63(18): 1693 - 1703. [Abstract] [Full Text] [PDF]

				D. K. Benjamin Jr., T. Driscoll, N. L. Seibel, C. E. Gonzalez, M. M. Roden, R. Kilaru, K. Clark, J. A. Dowell, J. Schranz, and T. J. Walsh Safety and Pharmacokinetics of Intravenous Anidulafungin in Children with Neutropenia at High Risk for Invasive Fungal Infections Antimicrob. Agents Chemother., February 1, 2006; 50(2): 632 - 638. [Abstract] [Full Text] [PDF]

				J. A. Dowell, J. Schranz, A. Baruch, and G. Foster Safety and Pharmacokinetics of Coadministered Voriconazole and Anidulafungin J. Clin. Pharmacol., December 1, 2005; 45(12): 1373 - 1382. [Abstract] [Full Text] [PDF]